Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000148 | 1.00 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29468874 | 1.00 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1001837 | 0.89 | KMT2A (0.46) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL97175 | 0.89 | KMT2A (0.46) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1001474 | 0.88 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1001475 | 0.88 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27587876 | 0.87 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL4388219 | 0.87 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL28719512 | 0.87 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27587878 | 0.87 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924431-A | Natural cyclopeptide zelkovamycins simplified substance and preparation method and application thereof | 北流市中医医院 | 2024-04-26 | — | — | CN | claimed |
| CN-117924431-A | Natural cyclopeptide zelkovamycins simplified substance and preparation method and application thereof | 北流市中医医院 | 2024-04-26 | — | — | CN | disclosed |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-05-16 | — | — | US | disclosed |
| EP-3436046-A2 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | The Regents of The University of California (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017173302-A2 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-05 | — | — | WO | disclosed |
| CN-105102475-A | Sodium channel sensitive conopeptides and analogs, including compositions and methods thereof | UNIV UTAH RES FOUND | 2015-11-25 | — | — | CN | disclosed |
| US-20150322120-A1 | SODIUM CHANNEL SENSITIVE CONOPEPTIDES AND ANALOGS, INCLUDING COMPOSITIONS AND METHODS THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2838913-A1 | SODIUM CHANNEL SENSITIVE CONOPEPTIDES AND ANALOGS, INCLUDING COMPOSITIONS AND METHODS THEREOF | University of Utah Research Foundation (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013158800-A1 | SODIUM CHANNEL SENSITIVE CONOPEPTIDES AND ANALOGS, INCLUDING COMPOSITIONS AND METHODS THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2001079167-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| CN-1313863-A | Inhibitors of urokinase and angiogenesis | CORVAS INTERNAT INC (US) | 2001-09-19 | — | — | CN | disclosed |
| US-5854410-A | Oligonucleoside cleavage compounds and therapies | GENTA INCORPORATED (US) | 1998-12-29 | — | — | US | disclosed |
| US-5846841-A | Motif Libraries | SELECTIDE CORPORATION (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0542887-B1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INC (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0542928-A4 | IMPROVED NON-NUCLEOTIDE-BASED LINKER REAGENTS FOR OLIGOMERS | GENTA INC (US) | 1994-07-27 | — | — | EP | disclosed |
| EP-0542928-A1 | IMPROVED NON-NUCLEOTIDE-BASED LINKER REAGENTS FOR OLIGOMERS | GENTA INCORPORATED (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0542887-A1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INCORPORATED (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992002641-A1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INCORPORATED (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002532-A1 | IMPROVED NON-NUCLEOTIDE-BASED LINKER REAGENTS FOR OLIGOMERS | GENTA INCORPORATED (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | ITGA5, ITGB5, ITGB1 | KMT2A 4454/4885FABP5 549/4885FABP7 3439/4885 |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | ITGA5, ITGB5, ITGB1 | KMT2A 4454/4885FABP5 549/4885FABP7 3439/4885 |
| US-20150322120-A1 | SODIUM CHANNEL SENSITIVE CONOPEPTIDES AND ANALOGS, INCLUDING COMPOSITIONS AND METHODS THEREOF | CACNA1B, CACNB2, CACNA1C | KMT2A 4043/4885FABP5 2527/4885FABP7 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.